Craig Crews

Craig Crews invented PROTAC (Proteolysis Targeting Chimera) technology, the revolutionary approach to drug development that uses bifunctional molecules to recruit E3 ubiquitin ligases to disease-causing proteins, inducing their degradation through the ubiquitin-proteasome system rather than traditional inhibition. He co-founded Arvinas, which advanced the first PROTACs into clinical trials: ARV-110 targeting the androgen receptor in prostate cancer and ARV-471 targeting the estrogen receptor in breast cancer. His catalytic degrader concept fundamentally changed drug discovery by enabling targeting of previously undruggable proteins. He continues to expand PROTAC technology to new targets and disease indications.